These malignant growths involve the neuroendocrine cells, which can both send out nerve signals and secrete hormones.
Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) represents a rare pulmonary disorder that is now recognised as a precursor lesion to neuroendocrine tumours, including carcinoids ...
Neuroendocrine tumors (NETs) represent a diverse group of neoplasms arising from neuroendocrine cells, most commonly affecting the gastrointestinal tract, ...
If you or a loved one has gastroenteropancreatic neuroendocrine tumors (GEP-NETs), you may be interested in learning about treatment options. One medicine you might hear about is Lutathera (lutetium ...
Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study The mammalian target of rapamycin (mTOR) ...
UCLA researchers have uncovered a hidden weakness in some of the deadliest cancers, revealing a potential new strategy for targeting tumors that have long resisted treatment. Small cell neuroendocrine ...
Symptoms of neuroendocrine tumors (NETs) can vary depending on their location and severity. General symptoms include extreme fatigue, unexplained weight loss, and loss of appetite. NETs are a rare ...
Genitourinary medical oncologist Dr. Michael Morris is part of a new MSK program focused on better treatments for neuroendocrine cancers, which sometimes develop when prostate and lung cancers become ...
DURHAM, N.C. – A new study reveals that small cell lung cancer (SCLC) likely begins in basal stem-like cells rather than in neuroendocrine cells, marking a major shift in the understanding of this ...
Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).
The global pancreatic neuroendocrine tumors (PNETs) market is experiencing significant growth driven by rising incidence rates, advances in diagnostic imaging, and expanding therapeutic options. PNETs ...